Novartis (Switzerland)

The Novartis Repository
Not a member yet
    7196 research outputs found

    PK/PD and Bioanalytical Considerations of AAV-Based Gene Therapies: an IQ Consortium Industry Position Paper.

    No full text
    Interest and efforts to use recombinant adeno-associated viruses (AAV) as gene therapy delivery tools to treat disease have grown exponentially. However, gaps in understanding of the pharmacokinetics/pharmacodynamics (PK/PD) and disposition of this modality exist. This position paper comes from the Novel Modalities Working Group (WG), part of the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ). The pan-industry WG effort focuses on the nonclinical PK and clinical pharmacology aspects of AAV gene therapy and related bioanalytical considerations.Traditional PK concepts are generally not applicable to AAV-based therapies due to the inherent complexity of a transgene-carrying viral vector, and the multiple steps and analytes involved in cell transduction and transgene-derived protein expression. Therefore, we explain PK concepts of biodistribution of AAV-based therapies and place key terminologies related to drug exposure and PD in the proper context. Factors affecting biodistribution are presented in detail, and guidelines are provided to design nonclinical studies to enable a stage-gated progression to Phase 1 testing. The nonclinical and clinical utility of transgene DNA, mRNA, and protein analytes are discussed with bioanalytical strategies to measure these analytes. The pros and cons of qPCR vs. ddPCR technologies for DNA/RNA measurement and qualitative vs. quantitative methods for transgene-derived protein are also presented. Last, best practices and recommendations for use of clinical and nonclinical data to project human dose and response are discussed. Together, the manuscript provides a holistic framework to discuss evolving concepts of PK/PD modeling, bioanalytical technologies, and clinical dose selection in gene therapy

    A rapid sterility method using solid phase cytometry for cell based preparations and culture media and buffers.

    No full text
    In this report, we introduce a rapid sterility testing method for cell-based preparations and its in-process control media/buffers. The selected Rapid Sterility Test (RST) in this work is based on the ScanRDI® system, which detects fluorescently labeled microorganisms with solid phase cytometry. ScanRDI® has been chosen due to its sensitivity for detecting viable microorganisms down to one microbial cell with a shorter time to detection compared to Compendial Sterility Test (CST) method. The RST was validated for a CAR-T cell-therapy product with 4 days of Time to Detection (TTD) and evaluated for in-process control of media/buffers with real time detection method successfully according to USP , Ph. Eur. 5.1.6, Ph. Eur. 2.6.27 and PDA Technical Report No. 33. The validation parameters included limit of detection and equivalence in routine operations, specificity, robustness, ruggedness and repeatability. For the validation, a combination of pharmacopoeial ATCC strains as well as in-house isolates were used. In addition, the evaluation study of this RST for in-process control of media/buffers was assessed by performing the limit of detection and equivalence with four representative microorganisms. Where applicable, results were statistically evaluated to demonstrate equivalence and no significant difference of the rapid method as compared to the CST method. All acceptance criteria of the validation/evaluation have been met and the solid phase cytometry technology was successfully validated as an alternative sterility test for cell-based preparations and its in-process control of media/buffer

    Hybrid modeling supported development of an industrial small-molecule flow chemistry process

    No full text
    Continuous manufacturing of small molecules finds increasing application in developing novel processes due to its significant advantages. The development of these processes is increasingly being supported by models, in a quest to reduce the number of experiments and increase insight. With the Quality by Design paradigm in mind, answers to questions anent the impact of changes in process parameters and material attributes on the process performance and product quality are sought to be answered. In this contribution, a hybrid model is used to describe the impact of raw material variations and process parameter changes on the product quantity and quality of flow chemistry process. The process model is then used for process optimization aiming at maximizing the product concentration. During the optimization, a constraint that accounts for the risk of model misprediction is considered to explore only process conditions for which the model can describe the process behavior. The obtained optimal conditions are in agreement with expectations and underline the potential for hybrid model-based process development

    Systematic Evaluation of Local and Global Machine Learning Models for the Prediction of ADME Properties.

    No full text
    Machine learning (ML) has become an indispensable tool to predict absorption, distribution, metabolism, and excretion (ADME) properties in pharmaceutical research. ML algorithms are trained on molecular structures and corresponding ADME assay data to develop quantitative structure-property relationship (QSPR) models. Traditional QSPR models were trained on compound sets of limited size. With the advent of more complex ML algorithms and data availability, training sets have become larger and more diverse. Most common training approaches consist in either training a model with a small set of similar compounds, namely, compounds designed for the same drug discovery project or chemical series (local model approach) or with a larger set of diverse compounds (global model approach). Global models are built with all experimental data available for an assay, combining compound data from different projects and disease areas. Despite the ML progress made so far, the choice of the appropriate data composition for building ML models is still unclear. Herein, a systematic evaluation of local and global ML models was performed for 10 different experimental assays and 112 drug discovery projects. Results show a consistent superior performance of global models for ADME property predictions. Diagnostic analyses were also carried out to investigate the influence of training set size, structural diversity, and data shift in the relative performance of local and global ML models. Training set and structural diversity did not have an impact in the relative performance on the methods. Instead, data shift helped to identify the projects with larger performance differences between local and global models. Results presented in this work can be leveraged to improve ML-based ADME properties predictions and thus decision-making in drug discovery projects

    Bipotent transitional liver progenitor cells contribute to liver regeneration.

    No full text
    Following severe liver injury, when hepatocyte-mediated regeneration is impaired, biliary epithelial cells (BECs) can transdifferentiate into functional hepatocytes. However, the subset of BECs with such facultative tissue stem cell potential, as well as the mechanisms enabling transdifferentiation, remains elusive. Here we identify a transitional liver progenitor cell (TLPC), which originates from BECs and differentiates into hepatocytes during regeneration from severe liver injury. By applying a dual genetic lineage tracing approach, we specifically labeled TLPCs and found that they are bipotent, as they either differentiate into hepatocytes or re-adopt BEC fate. Mechanistically, Notch and Wnt/β-catenin signaling orchestrate BEC-to-TLPC and TLPC-to-hepatocyte conversions, respectively. Together, our study provides functional and mechanistic insights into transdifferentiation-assisted liver regeneration

    Spatiotemporal Metabolic Liver Zonation and Consequences on Pathophysiology.

    No full text
    Hepatocytes are the main workers in the hepatic factory, managing metabolism of nutrients and xenobiotics, production and recycling of proteins, and glucose and lipid homeostasis. Division of labor between hepatocytes is critical to coordinate complex complementary or opposing multistep processes, similar to distributed tasks at an assembly line. This so-called metabolic zonation has both spatial and temporal components. Spatial distribution of metabolic function in hepatocytes of different lobular zones is necessary to perform complex sequential multistep metabolic processes and to assign metabolic tasks to the right environment. Moreover, temporal control of metabolic processes is critical to align required metabolic processes to the feeding and fasting cycles. Disruption of this complex spatiotemporal hepatic organization impairs key metabolic processes with both local and systemic consequences. Many metabolic diseases, such as nonalcoholic steatohepatitis and diabetes, are associated with impaired metabolic liver zonation. Recent technological advances shed new light on the spatiotemporal gene expression networks controlling liver function and how their deregulation may be involved in a large variety of diseases. We summarize the current knowledge about spatiotemporal metabolic liver zonation and consequences on liver pathobiology

    Harnessing Bile for Drug Absorption through Rational Excipient Selection.

    No full text
    Bile solubilization and apparent solubility at resorption sites critically affect the bioavailability of orally administered and poorly water-soluble drugs. Therefore, identification of drug-bile interaction may critically determine the overall formulation success. For the case of the drug candidate naporafenib, drug in solution at phase separation onset significantly improved with polyethylene glycol-40 hydrogenated castor oil (RH40) and amino methacrylate copolymer (Eudragit E) but not with hydroxypropyl cellulose (HPC) in both phosphate-buffered saline (PBS) and PBS supplemented with bile components. Naporafenib interacted with bile as determined by 1H and 2D 1H-1H nuclear magnetic resonance spectroscopy and so did Eudragit E and RH40 but not HPC. Flux across artificial membranes was reduced in the presence of Eudragit E. RH40 reduced the naporafenib supersaturation duration. HPC on the other side stabilized naporafenib's supersaturation and did not substantially impact flux. These insights on bile interaction correlated with pharmacokinetics (PK) in beagle dogs. HPC preserved naporafenib bile solubilization in contrast to Eudragit E and RH40, resulting in favorable PK

    Technical considerations for the implementation of the Multi-Attribute-Method by mass spectrometry in a Quality Control laboratory.

    No full text
    Multi-attribute methods employing mass spectrometry are applied throughout the biopharmaceutical industry for product and process characterization purposes but are not yet widely accepted as a method for batch release and stability testing under good manufacturing practice (GMP) due to limited experience and level of comfort with the technical, compliance and regulatory aspects of its implementation at quality control (QC) laboratories. Here, current literature related to the development and application of the multi-attribute method by peptide mapping liquid chromatography mass spectrometry (MAM) is compiled with the aim of providing guidance for the implementation of MAM in a QC laboratory. This article, focusing on technical considerations, is the first part of a two-tiered publication, whereby the second part will focus on GMP compliance and regulatory aspects. This publication has been prepared by a group of industry experts representing 14 globally acting major biotechnology companies under the umbrella of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Manufacturing & Quality Expert Group (MQEG)

    A novel HERC4-dependent glue degrader targeting STING

    No full text
    Stimulator of interferon genes (STING) is a central component of the pathway sensing the presence of cytosolic nucleic acids, having a key role in type I interferon innate immune response. Localized at the endoplasmic reticulum (ER), STING becomes activated by cGAMP, which is generated by the intracellular DNA sensor cyclic GMP-AMP synthase (cGAS). Due to its critical role in physiological function and its’ involvement in a variety of diseases, STING has been a notable focus for drug discovery. Recent advances in drug discovery allow the targeting of proteins previously considered “un-druggable” by novel mechanism of actions. Molecular glue degraders are defined as the compounds leading targeted protein degradation (TPD) by creating novel ligase-substrate interactions. Here, we identified AK59 as a novel molecular glue degrader for STING. A genome-wide, CRISPR/Cas9 knockout screen showed that the compound-mediated degradation of STING by AK59 is compromised by the loss of HECT and RLD domain containing E3 ubiquitin protein ligase 4 (HERC4), ubiquitin-like modifier activating enzyme 5 (UBA5) and ubiquitin like modifier activating enzyme 6 (UBA6). While UBA5 and UBA6 could be the auxiliary factors for AK59 activity, our results indicate that HERC4 is the main E3 ligase for the observed degradation mechanism. Validation by individual CRISPR knockouts, co-immunoprecipitations, as well as proximity mediated reporter assays suggested that AK59 functions as a glue degrader by forming a novel interaction between STING and HERC4. Furthermore, our data reveals that AK59 was effective on the most common pathological STING mutations that cause STING-associated vasculopathy with onset in infancy (SAVI), suggesting a potential clinical application of this mechanism. Thus, these findings not only reveal a novel mechanism for compound-induced degradation of STING but also utilize HERC4 as potential E3 ligase that for TPD, enabling novel therapeutic applications

    An active member of EFMC: The Division of Medicinal Chemistry and Chemical Biology of the Swiss Chemical Society

    No full text
    The Division of Medicinal Chemistry and Chemical Biology (DMCCB) of the Swiss chemical Society is an active contributor to the dynamism of the Swiss and European scientific community. Founded in 1987, it pursues its mission to foster relationships among its academic and industrial members, to facilitate exchange by organizing symposia and courses, and to encourage scientific excellence. This article presents the Division and highlights both its offer to the community and its participation in the activities of EFMC, the European Federation for Medicinal chemistry and Chemical biology

    0

    full texts

    7,196

    metadata records
    Updated in last 30 days.
    The Novartis Repository
    Access Repository Dashboard
    Do you manage Open Research Online? Become a CORE Member to access insider analytics, issue reports and manage access to outputs from your repository in the CORE Repository Dashboard! 👇